Halozyme drug tech gets company $30 million upfront, possibly hundreds of millions more

San Diego’s Halozyme Therapeutics will get $30 million upfront, with the possibility of hundreds of millions more, under a licensing agreement with a European biotechnology company announced Monday.

Argenx, based in the Netherlands, is licensing Halozyme’s technology, which allows intravenous drugs…